Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kalytera Therapeutics Inc (KLY.VN)

Kalytera Therapeutics Inc (KLY.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 25,696
  • Shares Outstanding, K 571,028
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,212 K
  • 60-Month Beta 2.77
  • Price/Sales N/A
  • Price/Cash Flow 950.47
  • Price/Book 9.03
Trade KLY.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings $0.00 on N/A
  • Latest Earnings Date 12/04/20
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.040 +12.50%
on 04/09/21
0.060 -25.00%
on 03/17/21
-0.005 (-10.00%)
since 03/09/21

Most Recent Stories

More News
Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns

SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or...

CLAS.VN : 0.025 (-16.67%)
OTC.VN : 0.325 (+3.17%)
KLY.VN : 0.045 (unch)
KALTF : 0.1100 (unch)
Claritas Announces Closing of Convertible Debenture Financing with Obsidian Global GP, LLC

SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the "Company" or "Claritas") is...

KLY.VN : 0.045 (unch)
CLAS.VN : 0.025 (-16.67%)
OTC.VN : 0.325 (+3.17%)
Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

Drug is Being Tested in Patients with Acute Respiratory Distress Syndrome (“ARDS”) Caused by COVID-19

KLY.VN : 0.045 (unch)
KALTF : 0.1100 (unch)
CLAS.VN : 0.025 (-16.67%)
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107

SAN FRANCISCO and TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTD) (the " Company " or " Claritas ") is pleased to announce that, subject to...

KLY.VN : 0.045 (unch)
KALTF : 0.1100 (unch)
CLAS.VN : 0.025 (-16.67%)
KALTD : 0.3092 (+3.07%)
Claritas Announces Grant of Stock Options to Directors and Officers

SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") announced that it granted stock options on...

KLY.VN : 0.045 (unch)
CLAS.VN : 0.025 (-16.67%)
CLAS : 10.17 (+0.20%)
KALTF : 0.1100 (unch)
Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107

Study Demonstrated that Nitric Oxide Administered to Patients with Severe COVID-19 Pneumonia Significantly Improved Oxygen Levels

KLY.VN : 0.045 (unch)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease

Claritas to Initiate Phase 1 Clinical Study of R-107 by August

KLY.VN : 0.045 (unch)
CLAS.VN : 0.025 (-16.67%)
KALTF : 0.1100 (unch)
Claritas Announces Effective Date for Share Consolidation

SAN FRANCISCO, July 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") is pleased to announce that the previously...

KLY.VN : 0.045 (unch)
CLAS.VN : 0.025 (-16.67%)
CLAS : 10.17 (+0.20%)
KALTF : 0.1100 (unch)
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation

SAN FRANCISCO and TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced that...

KLY.VN : 0.045 (unch)
CLAS.VN : 0.025 (-16.67%)
CLAS : 10.17 (+0.20%)
KALTF : 0.1100 (unch)
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics

SAN FRANCISCO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has entered...

KLY.VN : 0.045 (unch)
CLAS.VN : 0.025 (-16.67%)
CLAS : 10.17 (+0.20%)
KALTF : 0.1100 (unch)

Business Summary

Kalytera Therapeutics Inc is a clinical-stage specialty pharmaceutical company developing a portfolio of pharmaceutical products in Canada. It develops new treatments for a variety of diseases and disorders, by discovering, developing, manufacturing, and delivering human therapeutics.

See More

Key Turning Points

3rd Resistance Point 0.052
2nd Resistance Point 0.048
1st Resistance Point 0.047
Last Price 0.045
1st Support Level 0.042
2nd Support Level 0.038
3rd Support Level 0.037

See More

52-Week High 0.110
Fibonacci 61.8% 0.079
Fibonacci 50% 0.070
Fibonacci 38.2% 0.061
Last Price 0.045
52-Week Low 0.030

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar